Fenwick represented TrialSpark, a technology-driven pharma company that runs end-to-end clinical trials, in its $156 million Series C financing. The round was led by Sam Altman and Lachy Groom with participation from investors including Sequoia Capital, Thrive Capital, Casdin Capital, Dragoneer, Section 32, John Doerr, Spark Capital, Felicis Ventures, Sound Ventures and Arrowmark.
TrialSpark will use the funds to acquire and/or partner on clinical stage pharmaceutical assets to develop through their in-house clinical trial platform, and also to invest in biotech companies with promising drug candidates ready for development. More information can be obtained from the company's announcement.
The Fenwick transaction team was led by corporate partners Michael Esquivel and Faisal Rashid and included associates Will Black, Meredith Evancie and Grace Fernandez.